For US Healthcare Professionals Only
Filter
Bimekizumab Resulted in Sustained Improvements in Routine Assessment of Patient Index Data 3 (RAPID3) in Psoriatic Arthritis up to 3 Years
Bimekizumab in Patients with Psoriatic Arthritis Resulted in Sustained Efficacy Assessed Using Composite Outcome Measures to 3 Years
Skin/Joint Symptom Control and Patient-Reported Outcomes in Psoriatic Arthritis with Biologic/Targeted Synthetic Antirheumatic Drugs
Bimekizumab Long-Term Efficacy and Safety in Patients with Psoriatic Arthritis with Baseline Plaque Psoriasis/Nail Involvement to 3 Years
Long-Term Improvements with Bimekizumab Treatment up to 3 Years Assessed by Psoriatic Arthritis Impact of Disease (PsAID)-12
Markers of IL-17 Signaling in the Blood of Patients with Psoriatic Arthritis with Inadequate Response to Tumor Necrosis Factor Inhibitors
Bimekizumab Improves Skin Pain Over 3 Years in Hidradenitis Suppurativa: Data from BE HEARD EXT
Interim Results from an International Multicenter Observational Study of Real-World Bimekizumab Treatment of Psoriatic Arthritis